EMERYVILLE, Calif., and Cambridge, MA – June 2, 2015 − KineMed, Inc. and Pronutria Biosciences, Inc. announced today a collaboration under which KineMed will apply its dynamic proteomics platform to assist Pronutria in evaluating novel biologics designed to restore cellular homeostasis in amino acid biology.
Pronutria Biosciences is a clinical-stage biotechnology company pioneering a new class of therapeutics to mediate amino acid biology for patients facing serious diseases who currently have few or no treatment options. Pronutria is rapidly advancing research and development programs in several nutritional and therapeutic areas including myopenia (or muscle wasting), metabolic, neurological and liver disorders. Pronutria will utilize the KineMed platform to assess the physiologic effects of its compounds in preclinical and clinical studies. “KineMed’s ability to rapidly evaluate changes in protein balance is uniquely valuable in assessing the physiologic impact of our proteins in different conditions,” stated Robert Connelly, President and Chief Executive Officer of Pronutria.
KineMed’s dynamic proteomics platform is designed to rapidly detect target engagement, track disease progression and provide data that are predictive of later-stage clinical trial outcomes. “We look forward to providing important efficacy and safety information to Pronutria regarding the utility of their compounds across a variety of potential indications,” stated David M. Fineman, KineMed’s Chairman and Chief Executive Officer.
About KineMed, Inc.
KineMed is a life sciences company that is using its dynamic proteomics platform to develop drugs more efficiently and with less risk. Dynamic proteomics, in a single sample, rapidly detects target engagement, tracks disease progression and provides data that are highly predictive of late-stage success. The previously unavailable molecular biochemistry behind our non-invasive kinetic measurements is based upon the body’s metabolic incorporation of safe, non-radioactive tags into newly synthesized molecules through disease-modifying pathways. The rates, or activity, of these disease-modifying metabolic pathways are measured by highly sensitive mass spectrometric analytic techniques. Our technology platform, developed and validated over the past decade, establishes early proof-of-concept, target validation, pharmacodynamics, evidence of toxicity, and optimal dose. We apply our dynamic proteomics platform to our biopharma-partners’ drug assets as well as in advancing our own pipeline. For more information, please visit www.kinemed.com.
About Pronutria Biosciences
Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated. Pronutria Biosciences is developing first-in-class solutions to these conditions with a focus on amino acid biology. Using insights from a clinically validated body of evidence, we are pioneering new nutritional and therapeutic modalities: amino acid biologics. This novel approach allows us to precisely target biology that was previously inaccessible, providing a unique opportunity to address a variety of serious nutritional and medical conditions, such as myopenia (or muscle wasting), metabolic, neurological, liver disorders and inborn errors of metabolism. Founded by Flagship Venture Labs, privately held Pronutria Biosciences is based in Cambridge, MA. For more information, please visit www.pronutriabio.com.
Contact KineMed Corporate:
Tel: 510-655-6525 ext. 172
Contact Pronutria BioSciences